1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Abnova Taiwan Corp.

Abnova Taiwan Corp.

TTWSE:4133
20.60
TWD
-0.30
(-1.44%)
0.74EPS
27.61P/E
1.24BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
7.46
7.05
7.38
7.48
7.85
7.04
6.84
7.54
7.46
6.8
6.31
5.87
5.8
5.7
Basic EPS, GAAP
1.17
1.06
0.73
0.91
0.97
0.76
0.05
0.6
0.47
1.24
0.72
1.02
-0.02
0.74
Free Cash Flow per Basic Share
1.22
1.2
-1.55
-0.11
-0.34
0.08
1.01
1.61
1.52
2.08
0.78
0.71
-0.17
0.72
Dividend per Share
1.15
1.05
0.97
0.66
0.39
0.8
0.6
0.1
0.6
0.46
0.8
0.72
0.9
- -
Book Value per Share
19.8
19.8
19.78
19.42
20.23
20.27
19.69
20
20.01
21.34
21.24
21.62
20.75
21.03
Tangible Book Value per Share
19.18
19.3
19.2
18.84
19.81
19.23
18.55
18.83
18.89
20.2
20.09
20.59
19.77
20.08
Basic Weighted Avg Shares
62
62
61
59
61
61
61
61
61
61
61
61
61
61
Sales/Revenue/Turnover
464
438
451
440
475
426
414
456
451
412
382
355
351
345
Operating Margin (%)
17.09
14.26
11.32
11.03
12.42
5.08
7.21
13.48
9.97
15.82
11.55
9.45
4.97
6.18
Depreciation Expense
39
39
36
36
36
41
47
44
42
34
32
30
29
28
Net Income, GAAP
73
66
45
54
59
46
3
37
28
75
44
62
-1
45
Effective Tax Rate (%)
17.63
15.19
19
6.12
19.08
- -
- -
25.53
21.84
21.18
9.97
15.82
- -
4.99
Profit Margin (%)
15.72
14.98
9.95
12.17
12.41
10.83
0.79
8
6.28
18.18
11.43
17.34
-0.32
12.99
Working Capital
1,090
1,099
880
815
792
669
639
699
724
855
857
903
862
882
LT Debt
- -
- -
- -
- -
- -
- -
7
5
1
4
3
18
13
11
Total Equity
1,230
1,230
1,167
1,176
1,225
1,227
1,192
1,211
1,212
1,292
1,286
1,309
1,256
1,273
Return on Invested Capital (%)
5.29
4.29
3.41
3.85
3.94
- -
- -
3.51
2.78
4.02
3.27
2.2
- -
1.63
Return on Capital (%)
5.93
5.34
3.75
4.57
4.91
- -
- -
3.01
2.33
5.94
3.37
4.7
- -
3.56
Return on Common Equity (%)
5.93
5.34
3.75
4.57
4.91
3.76
0.27
3.04
2.34
5.98
3.39
4.75
-0.09
3.58

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
5
6
6
LT Borrowings
- -
- -
- -
LT Finance Leases
13
13
11
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
61
61
61
Market Capitalization
1,375
1,362
1,238

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
915
937
947
Cash, Cash Equivalents & STI
378
395
405
Accounts Receivable, Net
50
52
47
Inventories
469
470
478
Total Current Liabilities
54
66
65
Payables & Accruals
- -
- -
- -
ST Debt
5
6
6
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
0.79%
0.8%
-4.04%
Free Cash Flow
106.49%
-32.66%
-123.24%
Net Income, GAAP
97.31%
7.81%
-101.85%
Sales/Revenue/Turnover
-2.27%
-5.04%
-1.11%
Total Cash Common Dividend
48.91%
113.12%
25%

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
85
92
90
88
355
2025
90
92
85
84
351
2026
88
88
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.44
0.3
0.05
0.22
1.02
2025
0.22
-0.6
0.19
0.17
-0.02
2026
0.28
0.1
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.72
2025
- -
- -
- -
- -
0.9
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Pei Ju Jih
Full Time Employees
110
Sector
Health technology
Industry
Medical specialties
Address
No. 108, Jhouzih Street Taipei TPE Taiwan 114
IPO Date
Dec 28, 2009
Website
abnova.com.tw
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Abnova (Taiwan) Corporation principally engages in the manufacturing and sales of antibodies and recombinant proteins. The company's core product portfolio includes monoclonal antibodies, polyclonal antibodies, protein fragments, full-length proteins, active proteins, antibody pairs, fluorescence in situ hybridization probes, and related assay kits. It provides specialized antibodies such as MaxPab, recombinant, conjugate, secondary/tag, IHC/pathology, and circulating rare cell antibodies. Abnova also offers integrated services encompassing gene synthesis, cytogenetics, peptide synthesis, protein expression, conjugation, antibody production, and assay development. Its products serve applications in medical testing reagents, agricultural testing, industrial purification, medical treatment, protein engineering, and research sectors. The company operates primarily in Taiwan, the Americas, and Europe, targeting academic institutions, research organizations, and pharmaceutical manufacturers. Founded in 2002 and headquartered in Taipei, Taiwan, Abnova has recently expanded into cell therapy markets with the launch of CellTX cell therapy reagents, reflecting a strategic diversification aligned with pharmaceutical industry evolution. The company reported solid earnings in recent quarters despite some year-to-year net income variation, underlining ongoing operational resilience. Abnova maintains a commitment to high-throughput, industrialized antibody production leveraging advanced IT management systems to optimize laboratory practices and production scalability. This comprehensive product and service suite positions Abnova as a significant player in biotechnology reagents and customized biological research tools in the health care sector.